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Background: Heart failure with normal ejection fraction remains incompletely understood. Novel biomarkers may help in diagnosis and risk 
stratification.
Methods: A subgroup of patients from the ongoing Diast-CHF observational trial was selected with a history of chronic heart failure or positive 
Framingham criteria at presentation. Patients were classified as having systolic heart failure (SHF, n=86), diastolic heart failure according to 2007 
ESC criteria (DHF, n=143) or other heart failure (normal ejection fraction not meeting ESC criteria) (OHF, n=115). Groups were compared with elderly 
healthy controls (n=189) from the same cohort. Patients underwent testing for novel heart failure markers growth differentiation factor 15 (GDF-15), 
high-sensitive Troponin T (hsTropT) and mid-regional pro-Adrenomedullin (MRproADM) as well as NTproBNP, and comprehensive echocardiography at 
baseline.
Results: Novel heart failure markers were differentially elevated in SHF, DHF and OHF compared to controls (p<0.001 for all). Markers were 
higher in SHF compared to OHF (p<0.001 for all). hsTropT was higher in SHF compared to DHF (p<0.01), NTproBNP and MRproADM were higher 
in DHF than in OHF (p<0.001). All markers correlated with echocardiographic markers of systolic and diastolic function. Although NTproBNP is 
instrumentalized in the ESC criteria for DHF, ROC-curves for the presence of DHF showed the largest area under the curve for MRproADM (0.898) and 
GDF-15 (0.891). For the presence of OHF, all novel markers showed larger areas under the ROC-curve than NTproBNP, with the largest area identified 
for hsTropT (0.861). Patients with values below the respective cutoff for all four markers had a probability of < 2 % of having DHF and < 6 % of 
having OHF.
Conclusions: A significant number of patients with heart failure with normal ejection fraction does not meet the ESC criteria for DHF. Novel heart 
failure markers are elevated in DHF and OHF and may be useful for the diagnostic workup of these conditions.
